FDA approved AstraZeneca’s Brilinta to reduce the risk of stroke
The FINANCIAL -- AstraZeneca’s Brilinta (ticagrelor) has been approved in the US to reduce the risk of stroke, a leading cause of disability ...
ADVERTISEMENT
Tag: THALES Phase III trial
ADVERTISEMENT
Popular Last 24h
-
H.I.G. Capital Ramps Up Acquisition Strategy with Tech and Events Industry Plays
-
Future-Proofing Your Workplace: Adapting to the Needs of a Modern Workforce
-
Ampersand wins £22m five-year contract at London Zoo
-
Anurag Bajpayee’s Gradiant : The Water Tech Firm Rides Industrial Demand Toward Global Expansion
-
UK Government has ordered to freeze assets of additional 300 persons related to ISIL and AL-QAIDA
-
The London Diplomatic List, Addresses, Contacts & Working Hours
-
The Security Service of Ukraine lost the appeal in court to Alona Shevtsova, Ibox Bank
LATEST POSTS
LATESTINTERVIEWS
ADVERTISEMENT
